Fig. 1. Consort diagram of enrolled patients. n values represent the number of patients at each stage of the protocol.

±The safety population included all patients who received one or more doses of entinostat. The efficacy evaluable population included all patients in the safety population with measurable disease at baseline per RECIST v1.1. Three patients were not evaluable as patients came off the study due to toxicity before completing the first cycle of treatment without evidence of disease progression.